Bellissant E, Thuillez C, Pussard E, Giudicelli J F
Service de Pharmacologie Clinique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.
Clin Pharmacol Ther. 1992 Mar;51(3):308-19. doi: 10.1038/clpt.1992.27.
The effects of two oral doses of zabicipril, a new angiotensin converting enzyme inhibitor, on systemic (arterial pressure, heart rate, and cardiac output) hemodynamic parameters and regional (brachial, carotid and femoral arteries' diameters and flows) hemodynamic parameters and on biologic (plasma-converting enzyme and renin activities, catecholamines, and atrial natriuretic factor) parameters were noninvasively investigated and compared with those of a placebo in a double-blind crossover study performed in six healthy male volunteers. Although it did not affect the systemic hemodynamic parameters, zabicipril induced a strong peripheral vasodilation, significantly reducing brachial, carotid, and femoral resistances and increasing the corresponding blood flows from 3 or 4 1/2 hours to 9 hours. This vasodilation affected only the arterioles, not the large arteries, and resulted in a redistribution of cardiac output toward the three regional vascular beds. Zabicipril induced an early, potent, and long-lasting converting enzyme inhibition. Furthermore, zabicipril did not affect plasma catecholamines and atrial natriuretic factor.
在一项针对六名健康男性志愿者进行的双盲交叉研究中，对新型血管紧张素转换酶抑制剂扎西普利的两个口服剂量对全身（动脉压、心率和心输出量）血流动力学参数、局部（肱动脉、颈动脉和股动脉直径及血流量）血流动力学参数以及生物学（血浆转换酶和肾素活性、儿茶酚胺和心钠素）参数的影响进行了无创性研究，并与安慰剂的影响进行了比较。尽管扎西普利不影响全身血流动力学参数，但它可引起强烈的外周血管舒张，显著降低肱动脉、颈动脉和股动脉阻力，并使相应血流量从3或4.5小时至9小时增加。这种血管舒张仅影响小动脉，不影响大动脉，并导致心输出量重新分布至三个局部血管床。扎西普利可引起早期、强效且持久的转换酶抑制作用。此外，扎西普利不影响血浆儿茶酚胺和心钠素。
